Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher E M Griffiths

Showing results (211-220 of 337) with videos related to

Pageof 34
Sort By:
Journal of the American Academy of Dermatology|September 21, 2011
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trialsMark Lebwohl, Craig Leonardi, Christopher E M Griffiths, et al.
The Journal of Investigative Dermatology|November 13, 2013
Polymorphisms in IL-1B distinguish between psoriasis of early and late onsetHarry L Hébert, John Bowes, Rhodri L Smith, et al.
The Journal of Investigative Dermatology|February 8, 2008
Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasisRichard B Warren, Rhodri L L Smith, Emanuela Campalani, et al.
Cells|September 8, 2023
Human Mast Cells Upregulate Cathepsin B, a Novel Marker of Itch in PsoriasisPeter W West, Chiara Tontini, Haris Atmoko, et al.
JAMA Dermatology|December 2, 2020
Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators RegisterZenas Z N Yiu, Kayleigh J Mason, Philip J Hampton, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|September 5, 2015
'I should have taken that further' - missed opportunities during cardiovascular risk assessment in patients with psoriasis in UK primary care settings: a mixed-methods studyPauline A Nelson, Karen Kane, Anna Chisholm, et al.
The British Journal of Dermatology|May 10, 2023
Incidence and prevalence of generalized pustular psoriasis in multiethnic Johor Bahru, Malaysia: a population-based cohort study using routinely captured electronic health records in the Teleprimary Care (TPC®) clinical information system from 2010 to 2020Siew Eng Choon, Alison K Wright, Christopher E M Griffiths, et al.
Journal of Drugs in Dermatology : JDD|March 8, 2012
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-upKristian Reich, Kim A Papp, Christopher E M Griffiths, et al.
JAMA Dermatology|March 5, 2025
Effectiveness of Adalimumab Biosimilars and Originator for PsoriasisDuc Binh Phan, Anthony P Bewley, Philip Laws, et al.
Matrix Biology Plus|February 5, 2021
Proteomic fingerprints of damage in extracellular matrix assembliesAlexander Eckersley, Matiss Ozols, Ronan O'Cualain, et al.
Pageof 34

Showing results (211-220 of 337) with videos related to

Sort By:
Pageof 34
Journal of the American Academy of Dermatology|September 21, 2011
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trialsMark Lebwohl, Craig Leonardi, Christopher E M Griffiths, et al.
The Journal of Investigative Dermatology|November 13, 2013
Polymorphisms in IL-1B distinguish between psoriasis of early and late onsetHarry L Hébert, John Bowes, Rhodri L Smith, et al.
The Journal of Investigative Dermatology|February 8, 2008
Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasisRichard B Warren, Rhodri L L Smith, Emanuela Campalani, et al.
Cells|September 8, 2023
Human Mast Cells Upregulate Cathepsin B, a Novel Marker of Itch in PsoriasisPeter W West, Chiara Tontini, Haris Atmoko, et al.
JAMA Dermatology|December 2, 2020
Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators RegisterZenas Z N Yiu, Kayleigh J Mason, Philip J Hampton, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|September 5, 2015
'I should have taken that further' - missed opportunities during cardiovascular risk assessment in patients with psoriasis in UK primary care settings: a mixed-methods studyPauline A Nelson, Karen Kane, Anna Chisholm, et al.
The British Journal of Dermatology|May 10, 2023
Incidence and prevalence of generalized pustular psoriasis in multiethnic Johor Bahru, Malaysia: a population-based cohort study using routinely captured electronic health records in the Teleprimary Care (TPC®) clinical information system from 2010 to 2020Siew Eng Choon, Alison K Wright, Christopher E M Griffiths, et al.
Journal of Drugs in Dermatology : JDD|March 8, 2012
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-upKristian Reich, Kim A Papp, Christopher E M Griffiths, et al.
JAMA Dermatology|March 5, 2025
Effectiveness of Adalimumab Biosimilars and Originator for PsoriasisDuc Binh Phan, Anthony P Bewley, Philip Laws, et al.
Matrix Biology Plus|February 5, 2021
Proteomic fingerprints of damage in extracellular matrix assembliesAlexander Eckersley, Matiss Ozols, Ronan O'Cualain, et al.
Pageof 34